Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

213
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
213
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

684
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
684
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

355
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
355
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

326
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
326
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

611
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
611
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

594
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
594

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.

Biomedicines·2026
Same author

Long-Term Outcomes of Fenofibrate for Treatment of Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation.

Clinical transplantation·2025
Same author

Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Life (Basel, Switzerland)·2024
Same author

Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study.

Hepatology communications·2023
Same author

Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation.

Hepatic medicine : evidence and research·2022
Same author

Emerging therapies for PBC.

Journal of gastroenterology·2020
Same journal

Clinical Relevance and Utility of Serum APOC2 Levels in Patients with Type 2 Diabetes Mellitus: A Comparative Study on Subjects with and without Pyogenic Liver Abscess.

Hepatic medicine : evidence and research·2026
Same journal

Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells.

Hepatic medicine : evidence and research·2026
Same journal

2 Cases of Large Cystic-Solid Perivascular Epithelioid Cell Tumor: Case Report and Literature Review.

Hepatic medicine : evidence and research·2026
Same journal

Literature Review on the Regulatory Effects of Hydrogen Sulfide in Non-Alcoholic Fatty Liver Disease (NAFLD).

Hepatic medicine : evidence and research·2026
Same journal

The Prevalence of Liver Enzyme Abnormalities Among Adult Patients with Non-Communicable Diseases in Rwanda: A Gender-Stratified Analysis.

Hepatic medicine : evidence and research·2025
Same journal

Mapping the Intellectual Landscape: A 20-Year Bibliometric Analysis of Mechanisms in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Hepatic medicine : evidence and research·2025
See all related articles

Related Experiment Video

Updated: Dec 18, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.3K

Update on Emerging Treatment Options for Primary Biliary Cholangitis.

Maria T Aguilar1, David M Chascsa2

  • 1Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA.

Hepatic Medicine : Evidence and Research
|June 18, 2020
PubMed
Summary
This summary is machine-generated.

Primary biliary cholangitis (PBC) treatments are limited. While ursodeoxycholic acid (UDCA) is first-line, obeticholic acid (OCA) offers adjunct therapy, though pruritus is a concern. Fibrates show promise for PBC management.

Keywords:
fibrateobeticholic acidprimary biliary cholangitis

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.8K

Related Experiment Videos

Last Updated: Dec 18, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.3K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.8K

Area of Science:

  • Hepatology
  • Autoimmune Diseases
  • Gastroenterology

Background:

  • Primary biliary cholangitis (PBC) is a rare autoimmune liver disease.
  • It can lead to fibrosis or cirrhosis, with limited treatment options.
  • Current therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA).

Purpose of the Study:

  • To review current and emerging treatment options for PBC.
  • To discuss the efficacy and limitations of existing therapies.
  • To explore novel therapeutic strategies for PBC management.

Main Methods:

  • Literature review of clinical studies and therapeutic guidelines for PBC.
  • Analysis of treatment outcomes for UDCA, OCA, and fibrates.
  • Evaluation of symptom management strategies for pruritus and fatigue in PBC.

Main Results:

  • UDCA normalizes biochemistries and improves survival in PBC patients.
  • OCA serves as an adjunct therapy but may worsen pruritus.
  • Fibrates demonstrate promising results in ongoing studies for PBC treatment.

Conclusions:

  • Effective management of PBC requires addressing both disease progression and debilitating symptoms.
  • Novel therapies like fibrates are under investigation to expand treatment options.
  • Further research is needed to optimize PBC treatment and improve patient quality of life.